Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Investor Presentation (October 2026)
38 slides from Swedish Orphan Biovitrum Ab's investor presentation, October 2026
Slide 1: This is Sobi
This is Sobi D Investor presentation October 2026
Slide 2: Forward-looking statements
Forward-looking statements This presentation contains certain forward-looking statements with respect to certain of the Company’s current expectations and projections about future events. These statements, which sometimes use words such as “intend,” “proposed,” “plan,” “expect,” and words of similar
Slide 3: Table of contents
Table of contents Slide Sobi key facts and business model 4 Latest results – Q3 2026 and business area update 18 Sustainability at Sobi 29 Pipeline and upcoming news flow 33 IR contacts 36 Notes 37 3
Slide 4: Sobi: Global biopharma company developing and commercialising rare disease therapies
Sobi: Global biopharma company developing and commercialising rare disease therapies Clear strategy with proven execution: • Identify: Successful BD track record building pipeline via partnerships and acquisitions • Unlock: Deep clinical-stage pipeline spanning multiple rare disease areas • Level Up
Slide 5: Business model
Business model Sobi is a global biopharma company unlocking Level up the potential of breakthrough therapies, transforming everyday life for people living with rare diseases. Level up access to life changing treatments Unlock Unlock best-in-class therapies Identify Identify unmet medical needs and b
Slide 6: Sobi has built a materially stronger financial platform over the last years
Sobi has built a materially stronger financial platform over the last years Revenue and Adj EBITA margin evolution 2020 - 2025 2020 – 2025 Finance performance Revenue (B SEK) Adj EBITA margin • Key investments made in 2021–2023 30 120 paying dividends in 2025 and 28 +12% at CER 26 beyond 22 • Delive
Slide 7: Globalising our footprint to increase access and impact
Globalising our footprint to increase access and impact Sobi revenues1, SEK bn Sobi territories2 – coverage of >90% of Global Mkt.3 US +11% >100 launches across Sobi territories 9.3 5.5 in last 5 years 2020 2025 Europe +7% 10.8 9 new 7.6 organisations since 2020, 2020 2025 e.g. Japan, International
Slide 8: Sobi is entering a unique moment of opportunity, with big launches and 5 potential blockbusters
Sobi is entering a unique moment of opportunity, with 6 big launches and 5 potential blockbusters Timeline 2024 2025 2026 2027 2028 2029 2030 Haemophilia A HLH/MAS C3G & pIC-MPGN sHTG Uncontrolled gout NASP Progressive gout pozdeutinurad Joint Health / Synovitis1 Sézary syndrome lacutamab VEXAS2 IDS
Slide 9: Doubling Sobi to 55bn SEK by 2030
With such opportunities ahead we are setting a new ambition: Doubling Sobi to 55bn SEK1 by 2030 Revenue, in SEK bn ILLUSTRATIVE ONLY, NOT TO SCALE 6 major launches 55 Altuvoct in HA Gamifant HLH/MAS Priority Portfolio development renewal programs through NASP in BD uncontrolled gout Gamifant in IDS
Slide 10: We will further scale internationally to drive growth and diversify the business
We will further scale internationally to drive growth and diversify the business Europe + North America Pint acquisition as Share of Sobi business, in % of sales1 International move to further build LATAM presence • Established launch and 7% distribution platform for 16% >20% Sobi medicines • Accele
Slide 11: Leveraging our roots in rare disease and pivoting towards broader opportunities
Leveraging our roots in rare disease and pivoting towards broader opportunities The “Rare approach” remains at our Branching out from the rare core - examples core From To Deep scientific and medical foundation Patient-centric model built on long-term, pHLH IDS trusted physician partnerships Bra
Slide 12: Selected milestones and catalysts of the next years
Selected milestones and catalysts of the next years Status/ Peak sales Product Modality Indication Launch ambition Next milestones and catalysts Two modified SEK Launch in 16 countries in 2026-27; Haemophilia A Approved FREEDOM and SHINE data at EAHAD, FVIII biologics 10bn+ ISTH & ASH 2026 Mab targe
Slide 13: Financial framework
Financial framework Track record Our ambition until 2030 Revenue (B SEK) R&D % of Sales Revenue growth to Top-line growth key contributor to SG&A % of Sales Adj EBITA Margin maintaining strong margins and operating 30 60 55bn SEK by 2030 leverage 28 26 R&D to remain 50 Depending on portfolio evoluti
Slide 14: Capital allocation strategy
Capital allocation strategy Fund Organic Maintain balance Continue Shareholder Growth (R&D and sheet strength disciplined value SGA expenses to and financial business drive launches) flexibility development Primary use of cash Strong operating Selective and Increasing is reinvestment in cash flows a
Slide 15: Sobi represents a compelling investment opportunity with a clear path to sustained long-term growth
We want to double Sobi to SEK 55bn revenue by 2030, 1 with sustained growth beyond Sobi represents a After a period of investment, we expect adjusted compelling investment 2 EBITA margins to return to the upper-30% range opportunity with a clear path to sustained long- term growth and value We will
Slide 16: Management Team
Management Team Management Team sobi.com/executive committee Executive committee | Sobi 16
Slide 17: Latest results Q3 2026 and business area update
Latest results Q3 2026 and business area update
Slide 18: Strong portfolio growth and upgraded revenue outlook
Strong portfolio growth and upgraded revenue outlook 16% 23% 45% Q3 revenue growth YTD revenue growth Q3 adjusted EBITA margin (+26% ex RSV royalties) Altuvoct and Aspaveli launch progress Altuvoct +125%; Aspaveli reached its 2026 nephrology patient target by the end of Q3 Tryngolza: positive CHMP o
Slide 19: Strong growth delivered by our portfolio and across all regions
Strong growth delivered by our portfolio and across all regions +16% growth at CER (excluding seasonal RSV royalties +26%) Total net sales, SEK M, growth at CER Strategic portfolio, SEK M Revenue by region Doptelet 1 829 +29% Strategic1 +16% Foundational Europe 3,398 +25% 9,124 Altuvoct 1 729 +125%
Slide 20: Strong launch cadence and milestone achievement continues
Strong launch cadence and milestone achievement continues to strengthen Sobi’s differentiated portfolio Timeline New / update Q3/26 2024 2025 2026 2027 2028 2029 2030 Haemophilia A HLH/MAS Gamifant: Approved in Japan for HLH/MAS Aspaveli: : Approved in Japan for C3G and C3G & pIC-MPGN pIC-MPGN sHTG
Slide 21: Altuvoct: Growth of 125% at CER as its launch expanded
Altuvoct: Growth of 125% at CER as its launch expanded to 32 countries Haemophilia A sales SEK 2,345 M +48% Q3 Altuvoct: Launch progress • Altuvoct sales growth of +125% at CER • Launched in 32 countries, including key European markets Altuvoct launch in three waves: • Wave 1: Established in six cou
Slide 22: Aspaveli: Reached its 2026 nephrology patient target by Q3
Aspaveli: Reached its 2026 nephrology patient target by Q3, with sales up 32% Aspaveli SEK 417 M Sustained launch momentum +32% Q3 • Reached the 2026 target of 400–500 nephrology patients by the end of Q3 • Reimbursement available in several markets, including Germany, Spain and Japan • PNH performa
Slide 23: Beyfortus: Retains physician preference as the US RSV season begins
Beyfortus: Retains physician preference as the US RSV season begins amid uncertainty CDC Epidemic trends (Data presented through October 20, 2026)1 Early-season conditions remain mixed • RSV activity is rising across many states, • Competition and immunisation rates levels remain key uncertainties f
Slide 24: Doptelet & Gamifant: Continued strong momentum
Doptelet & Gamifant: Continued strong momentum SEK 1,829 M SEK 834 M +29% Q3 Doptelet +12% Q3 • Strong momentum and sustained growth across all three major regions • Expanding international launches across Japan, South Korea, Taiwan, LATAM, the Middle East, and Eastern Europe are expected to signifi
Slide 25: Significant progress in our International growth ambitions
Significant progress in our International growth ambitions Strengthening our presence in LATAM Building presence in strong Japanese market Pint Pharma Three approvals in 2026 Full ownership establishes a platform for Aspaveli for C3G and pIC-MPGN growth in Latin America Gamifant for HLH/MAS 2025 Dop
Slide 26: Sobi – Innate Pharma partnership advances Lacutamab in T-cell lymphoma
Sobi – Innate Pharma partnership advances Lacutamab in T-cell lymphoma Partnership overview Cutaneous T-cell lymphoma (CTCL) 1 Agreement Partnership enabling Phase 3 initiation Rare group of non-Hodgkin lymphoma, including •Sézary Syndrome (SS) Innate to conduct confirmatory Phase •Mycosis Fungoides
Slide 27: Guidance upgrade: raise full-year revenue guidance
Guidance upgrade: Strong year to date performance across the portfolio leading us to raise full-year revenue guidance Strong business performance Significant pipeline Portfolio progress progress Updated 2026 outlook in the first nine months Tryngolza High-teens to low-20s 23% Positive CHMP opinion i
Slide 28: Sobi Outlook 2026
Sobi Outlook 2026 Key drivers for 2026 outlook – Q3 update 2026 Updated Outlook • Progress with commercial portfolio and continued Altuvoct launch Revenue • YTD Growth 23% at CER Anticipated to grow by high-teens • Critical investments in 2026 for future to low-20s per cent at CER revenue growth: (p
Slide 29: Sustainability at Sobi
@sob! Sustainability at Sobi
Slide 30: Sustainability drives our strategic business priorities and decisions
Sustainability drives our strategic business priorities and decisions – progress Q3 2026 Patient commitment Responsible behaviour Main achievements Q3 2026 Ranked no. 1 in rare diseases for the • Access to treatment • Safe and healthy work second consecutive year in PatientView’s • Patient centricit
Slide 31: Commitment to patients
Commitment to patients For more details: Sustainability performance | Sobi Access to treatment Humanitarian aid Patient centricity >53,000 people* treated with • Four international patient councils a Sobi medicine in 2025 to advise on early clinical development. • 525 employees completed training Co
Slide 32: Always act responsibly
Always act responsibly For more details: Sustainability performance | Sobi Caring for employees Reduced footprint Responsible sourcing Compliance • Gender composition (%) A 77% reduction in CO2- intensity between 2016 and 95% Mean score 64 95% completed Code of 2023 (from 0,3 to 0,07 tonnes of Sobi’
Slide 33: Pipeline and upcoming news flow
Pipeline and upcoming news flow
Slide 34: Continued pipeline progress in Q3 2026
Continued pipeline progress in Q3 2026 HLH/MAS in Still’s disease Gamifant • Approved for MAS in Japan • New HLH data presented at Histiocyte Society Aspaveli / C3G & pIC-MPGN • Approved in Japan Empaveli • First participant enrolled in Phase 4 PRISM-C3 study Haemophilia A Altuvoct • Phase 4 ALTITUD
Slide 35: Progress to be continued in 2026-27
Progress to be continued in 2026-27 Anticipated pipeline news flow 2026 Q4 2027 Tryngolza – sHTG ≥880 mg/dL Pozdeutinurad – Progressive gout • EU regulatory decision • REDUCE 1&2 secondary data Gamifant – HLH / MAS in Still’s disease • EU regulatory decision Pozdeutinurad – Progressive gout • NDA su
Slide 36: Sobi IR contacts
Sobi IR contacts Investors page on sobi.com 36
Slide 37: Notes on Haemophilia and RSV business
Notes on Haemophilia and RSV business Haemophilia • Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or Altuviiio, in the US. • Sobi has final developme
Slide 38: Thank you
Thank you Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com
Swedish Orphan Biovitrum AB (Sobi) — Investor Presentation (October 2026) on 6ix